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Abstract 
 
Background 
Electroretinographic studies have suggested that anti-VEGF treatment apart from its positive 
impact on the diabetic macular oedema may have a more generalised impact on the entire retinal 
function.  
A portable, handheld, flash and flicker electro retinography (ERG) recording system has recently 
been developed (RETeval™ LKC Technologies, Gaithersburg, MD) that makes it possible to 
record ERGs more rapidly and less invasively than the conventional ERG systems.  
We evaluate ERG measurements by the RETeval device before and after treatment with intravitreal 
anti-VEGF injections in eyes with diabetic macular oedema associated with mild nonproliferative 
diabetic retinopathy.  
 
Methods 
Prospective pilot study of 7 eyes of 5 patients with type II diabetes treated for macular edema by 
intravitreal ranibizumab injections in Jules Gonin University Eye Hospital in Lausanne, 
Switzerland. ERGs were recorded with the RETeval system before treatment and 1 month after 
the 3rd injection. Measurements included responses to photoptic flicker and ERG recording 
according to various protocols including photopic negative response (PhNR), ERGs recorded by 
sinusoidal light stimulus and the RETeval specific diabetic retinopathy Assessment Protocol. 
Additionally, fluorescein angiography was performed on each patient before and after treatment. 
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Results  
All patients demonstrated significant improvement of visual acuity and resolution of macular 
oedema after treatment. We found no significant differences of the amplitudes and implicit times 
of ERGs after intravitreal injection of anti-VEGF with most of the protocols applied bar ERGs 
recorded by sinusoidal light stimulus. The mean implicit time of the flicker ERGs recorded by 
sinusoidal light stimulus was shortened significantly from 30.2 msec (SD: 0.6) at baseline to a 
mean of 29 msec (SD:0.76,) after the last intravitreal injection (p< 0.05; paired t-test).  
Additionally, the RETeval specific diabetic retinopathy Assessment Protocol designed to aid in the 
detection of vision threatening diabetic retinopathy including clinically significant macular 
oedema, could detect improvement in 71% of our cases. 
 
Conclusion 
In the present study we found no significant difference of the amplitudes and implicit times by 
most protocols applied bar shortening of the implicit times after ranibizumab treatment using a 
sinusoidal light stimulus. It is believed that sinusoidal stimulus is sensitive to inner-retinal function 
though its significance is not yet clearly elucidated. Additionally, the RETeval specific DR 
Assessment Protocol could detect improvement in the majority of our cases. The RETeval device 
offers a novel, quick and easily accessible method of objective electroretinographic measurements 
though the significance of its clinical role warrants further studies. 
 
Keywords: Diabetic retinopathy, Diabetic macular oedema, ranibizumab, Flicker 
electroretinogram, RETeval 
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Introduction 
Diabetic retinopathy (DR) is the leading cause of blindness in adults of working age and diabetic 
macular oedema (DMO) is the most common vision-threatening manifestation of diabetic 
retinopathy (1-3). 
The complex pathophysiology of DMO has been under investigation in recent years. In individuals 
with diabetic retinopathy, fluid can accumulate within the central retina as a result of a breakdown 
in the blood–retinal barrier. Hyperglycaemia is associated with detrimental effects on the retinal 
vasculature (4) causing capillaries occlusion and ischemia with subsequent local hypoxia (5). 
Vascular endothelial growth factor (VEGF) plays a pivotal role in the retinal microvascular 
complications of diabetes (6-7). 
In parallel, several studies showed that neurodegeneration is also part of the physiopathology of 
RD and includes among others neural apoptosis, retinal ganglion cell loss, reactive changes in 
macroglia and thinning of the inner retina (8-10). 
Interestingly several studies have advocated that neurodegeneration appears in its early stages and 
it has even been suggested that inner retina alterations happen in type 2 diabetes, even before visible 
vascular signs of DR (11). 
It has been advocated that VEGF, apart to its role in the retinal microvascular complications of 
diabetes, can also display neurodegenerative and neuroprotective characteristics (12-13). 
Currently, therapeutic proteins designed to inhibit and/or neutralize VEGF have become the 
leading treatment modality for diabetic macular oedema (14-16).  
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Interestingly, it has been suggested by some ERG studies that	anti-VEGF treatment	may	have	-	
apart from the anatomic and functional improvement of the macula in the cases of diabetic 
macular oedema - an impact on the entire retinal function (17-19).  
 
 
A portable, handheld, flash and flicker ERG recording system has recently been developed 
(RETeval™ LKC Technologies, Gaithersburg, MD) that use adhesive skin electrodes as the active 
electrodes. This system makes it possible to record ERGs more rapidly and less invasively than the 
conventional ERG systems with contact lens electrodes. The RETeval device combines flicker 
electroretinogram (ERG) and pupillary responses (20). 
Patients with diabetes may have an altered response to flicker stimulation through several 
mechanisms (21) such as the dysfunction of neurons and photoreceptors 
and the reduced vasodilatator capacity of the retinal vessels in response to flicker stimulation (22). 
 
Thus, the aim of this pilot study was to compare ERG measurements recorded by the RETeval 
device before and after treatment with intravitreal anti-VEGF injections in eyes with diabetic 
macular oedema associated with mild nonproliferative diabetic retinopathy. We also evaluated 
angiographic findings and as well functional and anatomic changes assessed with ocular 
coherence tomography during follow-up. We also aimed to assess the specific diabetic 
Assessment Protocol. 
 
 
 
 
  
.                                                 Handheld ERG in diabetic macular edema.                          M.Abdulghafor et al. 6 
Methods 
Subjects 
Seven eyes of 5 patients with type II diabetes, who attended the diabetic retinopathy clinic of the 
Jules-Gonin University Eye Hospital in Lausanne, Switzerland were enrolled in this pilot 
monocentric prospective nonrandomized study. Inclusion criteria comprised macular oedema in 
the context of DR who were eligible for intravitreal ranibizumab injections and who were 
receiving this treatment for the first time.  
The exclusion criteria were the following: 1. Other co-existing or previous ocular disease that, in 
the opinion of the recruiting ophthalmologist, could affect the electrophysiologic test (such as 
optic neuropathy and vascular retinopathies), 2. known allergy to anticholinergic mydriatic drugs, 
3. current or previous use of systemic drug with potential retinal toxicity, 4. previous retinal laser 
treatment, 5. history of photosensitive epilepsy, 6. inability to follow procedures, for example 
dementia.  
A written study information leaflet was provided to all participants while all patients gave an 
informed written consent regarding their participation in the study and their treatment. 
Our study respects the tenets of Declaration of Helsinki while approval for the study was obtained 
from the local ethic committee.  
 
Procedures 
At the time of the first examination (baseline), a short entry questionnaire permitted to record the 
duration of diabetes, type of diabetes, type of diabetes treatment and levels of glycosylated 
haemoglobin. Subsequently, the patients underwent a clinical examination, which included visual 
acuity testing, intraocular pressure measurements, slit lamp and fundus examination. Auxiliary 
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tests included OCT, wide field fundus colour photography and fluorescein angiography. Each study 
participant had a complete ocular examination and repeated all auxiliary tests four weeks after the 
last injection.  
Intravitreal injections of 0.5 mg ranibizumab were given three times, every fourth week, starting 
within 1 week of the baseline examination. All patients underwent the same procedure: 0.5 mg 
ranibizumab was administered in a standardized way.  
 
Electrophysiologic testing 
The electrophysiologic testing of the retina was performed using a commercially available and CE- 
approved device: RETeval (LKC Technologies, Inc., UK). The device was used following the 
manufacturer’s recommendations. It consists of a hand-held, battery powered stimulator and 
recorder. The instrument uses disposable sensor strips placed 2 mm away from the lateral half of 
the lower eyelid margin. The lead is connected to the sensor strip to measure the eye’s electrical 
response.  
The RETeval device tested each eye with 16, and 32 Td·s flicker stimuli (28.3 Hz) that each 
lasted between 5 and 15s, depending on the standard error of mean for the implicit time 
measurement. Skin electrodes were used to pick up the ERGs that were elicited by white light 
delivered at the frequency of 28.3 Hz.  
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The RETeval device enables the changing of the stimulus conditions supporting different protocols. 
Additional protocols applied included photopic negative response (PhNR), ERGs recorded by 
sinusoidal light stimulus and the RETeval specific diabetic retinopathy assessment protocol. 
 
For the PhNR test the stimulus consisted of brief (<4 ms), red-flashes (1.6 cd.s/m2) on a steady 
blue background (photopic 10 cd/m2).  
Concerning the sinusoidal test sinusoidal stimuli can be generated with LKC’s patented Troland-
based technology for providing consistent retinal illumination independent of pupil size.  
The amplitudes and implicit times were automatically extracted and displayed by the RETeval 
system using an embedded algorithm.  
The DR Assessment Protocol is designed to aid in the detection of vision threatening diabetic 
retinopathy (DR), which is defined as severe non-proliferative DR, proliferative DR or clinically 
significant macular edema. The DR Assessment Protocol uses sets of flickering white stimuli (28.3 
Hz) with no background light. The number of sets is determined by the device’s internal precision 
metrics. The RETeval-DR device measures the pupil size in real time and continuously adjusts the 
flash luminance to deliver the desired amount of light into the eye regardless of the size of the 
pupil.  
The score produced by the DR Assessment Protocol correlates with the presence and severity of 
diabetic retinopathy and clinically significant macular edema (20). 
 
 
.                                                 Handheld ERG in diabetic macular edema.                          M.Abdulghafor et al. 9 
The significance of the differences in the amplitudes and implicit times between before and after 
IVR was determined by paired t-tests. A commercially available software (SPSS v.25 for mac; 
SPSS Inc., Chicago, IL) was used for all statistical analyses. A p < 0.05 was considered significant. 
 
Results  
The pilot study included 7 eyes of 5 male patients with a mean age of 69.5 years (range, 56 to 82 
years). All patients, had type-2 diabetes on insulin treatment. All eyes presented mild non-
proliferative diabetic retinopathy. Duration of diabetes was years 17 years (SD: 9 years). 
Fasting blood glucose and blood pressure levels did not change significantly between the 
examinations. 
At baseline, the mean visual acuity was 0.27 logMAR units (0.54 decimal equivalent) with a range 
of 0.4 to 0.2 logMAR units. Mean, baseline foveal thickness evaluated by OCT was 440 µm with 
a range of 308 to 731 µm.  On the last follow-up examination one month after the last intravitreal 
injection, the mean visual acuity improved significantly to 0.029 logMAR units (0.93 decimal 
equivalent) with a range of 0.1 to 0 logMAR units.  The mean foveal thickness determined by OCT 
was reduced to 319 µm with a range of 229 to 452µm. 
We found no significant difference of implicit times or the amplitudes of the flicker ERG before 
and after the IVR with neither of the different flicker stimuli used (16, and 32 Td·s).  
Regarding the stimulus flash retinal illuminance of 16 photopic Td-s, the mean implicit time was 
32.6 msec, SD: 0.69) at baseline versus 32.8 msec, SD: 0.75 after treatment p: 0.7, paired t-test) 
For the PhNR test the mean implicit time for the a-wave was 14.1ms SD:05, at baseline versus 
14ms SD:0.9 after treatment. (p:0.663 paired t-test) The mean a-wave amplitude was 4.2uV, SD:3.1 
at baseline versus 4.3uV, SD:2.9   (p:0.844 paired t-test). 
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The mean b-wave, mean implicit time was 33.8ms at baseline SD:1.4 ms versus 33.5ms SD:1.4ms 
after treatment. (p:0.681 paired t-test). The mean b-wave amplitude was 21uV, SD:0.7 at baseline 
versus 20uV, SD:0.8 (p:0.576 paired t-test). 
 
The mean implicit time of the flicker ERGs recorded using the sinusoidal test  
at baseline by the RETeval system was 30.2 msec (SD: 0.6, msec, MSE: 0.2).  
On the last follow-up examination one month after the last intravitreal injection, the implicit times 
of the flicker ERGs on the treated eye recorded with the RETevalTM system were significantly 
shortened to a mean 29 msec (SD:0.76, SEM:0.28 msec) (p< 0.05; paired t-test). (Figure 1, Figure 
2) The difference of the amplitudes of the flicker ERG before and after the IVR was not statistically 
significant 9.6 (SD:5.2) versus 9.1 (SD:4.5); paired t-test, p = 0.67 
 
The score produced by the DR Assessment Protocol was significantly reduced in 5 of the 7 eyes. 
(Figure 3).  
 
Discussion 
Numerous studies have shown improvement in visual acuity and decrease in central retinal 
thickness (CRT) after intravitreal injections of ranibizumab in diabetic patients presenting macular 
oedema (23). 
Emerging data suggest that ranibizumab may have, apart from its beneficial effect on CRT 
reduction, a favourable effect in DR severity indicating a beneficial effect on the entire retina (24-
25). 
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Full-field electroretinography is an objective method for registration of the overall retinal function. 
Nevertheless, very few ERG studies after ranibizumab treatment exist in the medical literature. 
The flicker ERG is a response from the cone system, and is therefore representative of the 
whole retina. While cone density in the fovea show a 40-fold increase, the area of the fovea is quite 
small (3.6 mm2 out of 1000 mm2) and the rest of the retina is relatively uniform in cone density. 
Changes in these ERG parameters have been correlated with DR severity. (20-26) More precisely, 
DR progression has been associated with a prolongation of the implicit time and a decrease of the 
amplitude (20). 
 
In 2015, Holm K. et al. found a significant decrease in cone implicit time with 30-Hz flicker 1 
month after the third injection of ranibizumab in patients with diabetic macular oedema using a 
visual evoked response imaging system according to the standardized protocol for clinical 
electroretinography by the International Society for Clinical Electrophysiology of Vision (ISCEV) 
(17). 
On the other hand, in 2014 Comyn O. et al in a randomized trial to assess functional and structural 
effects of ranibizumab versus laser in diabetic macular edema demonstrated that global retinal 
function, measured by full-field ERG, showed no significant change after treatment (27). 
Changes in 30-Hz flicker have also been described in other retinal diseases. 
In central vein occlusion, a correlation between retinal ischemia and delayed 30-Hz flicker implicit 
time has been shown (28-29). It has been hypothesized that these studies may indicate that an 
increased 30-Hz flicker implicit time indicates damaged cone function of the entire retina in the 
form of ischemia (17). 
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Pedersen et al.  examined the effect on the electroretinogram after injections of bevacizumab in 
patients with age-related macular degeneration and they found significant improvement in the 
implicit time of the cone flicker response at 6-month follow-up (30). 
In another study Neubauer et al. (31)  reported a significant decrease of peripheral ischaemia 1 
month after intravitreal anti-VEGF (bevacizumab) injection in eyes with diabetic retinopathy. It 
has been suggested that improvement of the peripheral retinal ischaemia after anti-VEGF therapy 
may be accountable for the shortening of the implicit times of the flicker ERGs recorded by 
RETeval devise after anti-VEGF treatment in eyes presenting central retinal vein occlusion (32). 
In the present study we have used a novel flicker ERG recording system allowing to record ERGs 
more rapidly and less invasively in diabetic retinopathy than the conventional ERG systems which 
are cumbersome and which require a contact lens on the cornea after local anaesthesia. Previous 
studies concluded that the novel RETeval device is a reliable tool with reasonable accuracy in 
comparison with the conventional ERG (33). 
 
In the present study, we did not find a significant decrease in 28-Hz of the cone flicker response 
implicit time 1 month after the third injection of ranibizumab in diabetics treated for macular 
oedema. 
Maybe this result reflects the fact that our study included only patients presenting mild non-
proliferative diabetic retinopathy with no signs of ischemia as demonstrated by the Optos wide 
field angiography. Consequently, no improvement of ischemic retinal areas could take place and 
therefore no shortening of the cone implicit time could be detected. Furthermore, in a recent study 
McAnny et al. suggested that flicker ERG  
of approximately 30 Hz, the frequency recommended by international 
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standards may not be able to detect ERG changes in mild nonproliferative DR and that high-
frequency flicker ERG may be more appropriate (34). 
 
Two of the protocols applied in this pilot study are supposedly related to inner retinal function; the 
PhNR test and the sinusoidal test. 
Several studies have suggested that neurodegenerative alterations of the inner retina happen in type 
2 diabetes, even before visible vascular signs of DR (11). Animal studies also suggested that 
neurodegeneration leading to inner retinal thinning is not limited to cell death and tissue loss but 
also includes changes in neuronal morphology, reduced synaptic protein expression and alterations 
in neurotransmission, including changes in expression of neurotransmitter receptors as well as 
neurotransmitter release, reuptake and metabolism (35). 
Bressel et al. showed that individuals receiving ranibizumab therapy for diabetic macular edema 
may have favourable changes in DR severity concomitant with sequential reduction in anti-vascular 
endothelial growth factor therapy (25). 
Joachim, S. C. et al. demonstrated that photoreceptors and retinal ganglion cell number are 
protected by ranibizumab treatment (12). 
 
The photopic negative response (PhNR) of the full-field electroretinogram (ERG) is a slow 
negative potential following the a- and b-waves that has been reported to originate primarily from 
the retinal ganglion cells (RGCs) and their axons (36). 
In the present study we did not find any difference in photopic negative response before and after 
treatment in our patients. It has been recently suggested that some corrections should be 
incorporated into signal processing protocols to improve PhNR recording and enhance its clinical 
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use (37). Therefore, it could be possible that our PhNR results were not optimally recorded and 
their validity might have been compromised.  
Kim et al. demonstrated that PhNR amplitude was reduced and the implicit time was prolonged in 
DR patients compared to those of normal subjects (38). 
Similarly, Chen et al found significant reduction of PhNR amplitude in diabetic compared to the 
control group. However, they found that this decrease in PhNR amplitude was not significantly 
different among groups with different stages of diabetic retinopathy (39). However, Kizawa et al 
found that PhNR progressively decrease with the progression of diabetic retinopathy (40). 
Further studies may be warranted to determine optimal signal processing protocols of PhNR 
recordings and its clinical significance in diabetic retinopathy. 
 
Interestingly though, the implicit times of the flicker ERGs recorded using the sinusoidal test of 
the RETeval system were significantly shortened after treatment to all patients.  
The harmonics of flicker ERG test results elicited from a sinusoidal light stimulus is believed to 
originate in the inner retina (41), and therefore this finding may indicate an improvement of the 
inner retinal function. Though, the role of flicker ERG test results elicited from a sinusoidal light 
stimulus has not been extensively studied and consequently its significance is not yet clearly 
elucidated.  
We furthermore evaluated ERG recordings applying the RETeval specific diabetic retinopathy 
assessment protocol that was developed using measurements of 467 people with diabetes aged 23 
– 88 (20). It has been advocated that the score produced by the DR Assessment Protocol correlates 
with the presence and severity of diabetic retinopathy and clinically significant macular edema.  In 
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our cases the DR Assessment Protocol of the RETeval devise could detect improvement in about 
71% of our cases although it failed to detect the improvement in 2 of the 7 cases. 
 
One limitation is the limited number of patients included in this pilot study. Although previous 
studies concluded that the novel RETeval device is a reliable tool with reasonable accuracy in 
comparison with the conventional ERG, further studies are warranted in order to establish its 
accuracy in a wider context and to evaluate the significance of its various protocols in clinical 
practice. 
 
In conclusion, in the present study we found no difference of the amplitudes and implicit times of 
flicker ERGs with any of the protocols applied bar shortening of the implicit times after 
ranibizumab treatment applying a sinusoidal light stimulus. These findings could theoretically 
indicate changes to inner-retinal function after intravitreal injection of ranibizumad in our diabetic 
patients, though the significance of the sinusoidal test is not yet clearly elucidated and these results 
should be interpreted with caution. 
The DR Assessment Protocol of the RETeval devise could detect improvement in about 71% of 
our cases. 
The RETeval devise offers a novel, quick and easily accessible method of objective 
electroretinographic measurements though its clinical significance warrants further studies. 
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Annex 
 
 
Figure 1. Implicit times of the flicker ERGs before and after IVR recorded with the sinusoidal test 
of RETevalTM system.  One month after the 3rd IVR, the implicit times of the flicker ERGs 
recorded by the RETevalTM system were shortened for all 7 patients.   
 
Figure 2. ERG of patient 1 recorded with the sinusoidal test the RETevalTM system at baseline 
and one month after the 3rd intravitreal injection of ranibizumab. Implicit time reduced from 30.3 
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ms to 28.6 ms. The black curve represents the electrical response of the eye to the flickering light 
(Waveform). The red dashed curve represents the fundamental of the electrical response. The 
rectangular box represents reference intervals that enclose 95% of the data in the visually-normal 
test population. Measurements of times and amplitudes are evaluated from the best-fitting sine 
wave to the waveform at the stimulus frequency (the fundamental of the response). 
 
Figure 3. The score produced by the DR Assessment Protocol was significantly reduced to 5 of the 
7 eyes. 
 
